Loading
CoStim Pharmaceuticals worked on antibodies that remove the signals cancers use to switch off the immune system, including against PD-1. Novartis bought it in 2014 while its programmes were still in the laboratory.
CoStim Pharmaceuticals was a privately held Cambridge, Massachusetts company focused on harnessing the immune system to remove immune-blocking signals from cancer. Novartis announced its acquisition on 17 February 2014, adding late-discovery-stage immunotherapy programmes directed at several targets including PD-1, to complement its CAR-T work with the University of Pennsylvania; terms were not disclosed. Atlas Venture lists CoStim as developing antibodies for immuno-oncology, sold to Novartis in 2014, and an Atlas partner's blog post says it was founded in 2012.
Shares Atlas Venture, Novartis.
Shares Novartis, Immune checkpoint inhibitors.
Shares Novartis, Immune checkpoint inhibitors.
Shares Novartis, Immune checkpoint inhibitors.
Shares Atlas Venture, Novartis.
Shares Novartis, Immune checkpoint inhibitors.
Shares Novartis, PD-1, Immune checkpoint inhibitors.
Shares Novartis, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/